Impact and Adoption of Momelotinib in Myelofibrosis


Pharmacists analyze the role of momelotinib in treating anemia in myelofibrosis, exploring its place in practice and impact on patient care amid emerging therapies.

This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In this Pharmacy Times® Peer Exchange, led by Mahmoudjafari, Nachar discusses the MOMENTUM trial, highlighting momelotinib’s efficacy in reducing symptoms and achieving transfusion independence in myelofibrosis patients. Griffin emphasizes momelotinib’s inclusion in National Comprehensive Cancer Network guidelines and envisions its role in treating severely symptomatic anemia. The speakers agree on the use of momelotinib for patients receiving Janus kinase inhibitors and those in rural settings facing access challenges. Davis praises momelotinib’s approval and its potential to reduce transfusions amid shortages. The discussion also touches on emerging therapies and research advancements in myelofibrosis.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.